614 McKinley Place N.E.
225 articles with Bio-Techne
Bio-Techne Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serology Assay Kit For Simple Western
New serology assay accelerates COVID-19 research and vaccine development through rapid characterization of human immune response to multiple SARS-CoV-2 antigens
Bio-Techne Corporation, a leading provider of proteins, antibodies and cytokines announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems.
Bio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results
Bio-Techne Corporation announced that management will host a conference call and webcast on Thursday, November 5, 2020, at 8:00 a.m. CST to review first quarter 2021 financial results.
Bio-Techne Corporation announced the opening of its new Canadian office located in Toronto.
Bio-Techne Corporation announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP manufacturing facility.
Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy
Bio-Techne Corporation announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample
Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAs
Bio-Techne Corporation announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™, will be rebranded as R&D Systems.
Bio-Techne Corporation and QIAGEN N.V. announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint development of new exosome based products.
Bio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer
Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr. This year marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought to be unbreakable record of 2,130 set by the legendary Lou Gehrig.
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT.
Bio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope™ COVID-19 Probes and the BOND RX*
Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica's staining platform, for research use only. Researchers now have the a
Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody™ Recombinant Antibody that Blocks Viral Entry
Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection . The SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Ant
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
Curated Menu of Off-the-Shelf RNAscope Probes Provide Seamless Molecularly-Guided Region of Interest Selection for Use With the New NGS-Enabled Cancer Transcriptome Atlas
Bio-Techne And NanoString Announce Offering Of RNAscope Reagents Validated For Use With The GeoMx Digital Spatial Profiler
Curated Menu of Off-the-Shelf RNAscope Probes Provide Molecularly-Guided Region of Interest Selection for Use with the New NGS-Enabled Cancer Transcriptome Atlas
The company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2020.
Bio-Techne Corporation announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective as of July 31, 2020.
Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
Bio-Techne Corporation and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC, announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit.
Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus and now offers the ExoCovid-19 test for detection of the virus in patient samples.